- Home
- EDUC vs IMNN Comparison
EDUC vs IMNN Comparison
Compare EDUC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- IMNN
- Stock Information
- Founded
- EDUC 1965
- IMNN 1982
- Country
- EDUC United States
- IMNN United States
- Employees
- EDUC N/A
- IMNN N/A
- Industry
- EDUC Consumer Specialties
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- IMNN Health Care
- Exchange
- EDUC Nasdaq
- IMNN Nasdaq
- Market Cap
- EDUC 10.1M
- IMNN 12.1M
- IPO Year
- EDUC N/A
- IMNN 1985
- Fundamental
- Price
- EDUC $1.30
- IMNN $0.60
- Analyst Decision
- EDUC
- IMNN Strong Buy
- Analyst Count
- EDUC 0
- IMNN 2
- Target Price
- EDUC N/A
- IMNN $15.50
- AVG Volume (30 Days)
- EDUC 12.7K
- IMNN 237.6K
- Earning Date
- EDUC 07-10-2025
- IMNN 05-12-2025
- Dividend Yield
- EDUC N/A
- IMNN N/A
- EPS Growth
- EDUC N/A
- IMNN N/A
- EPS
- EDUC N/A
- IMNN N/A
- Revenue
- EDUC $36,523,200.00
- IMNN N/A
- Revenue This Year
- EDUC N/A
- IMNN N/A
- Revenue Next Year
- EDUC N/A
- IMNN N/A
- P/E Ratio
- EDUC N/A
- IMNN N/A
- Revenue Growth
- EDUC N/A
- IMNN N/A
- 52 Week Low
- EDUC $0.92
- IMNN $0.64
- 52 Week High
- EDUC $2.49
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- EDUC 53.24
- IMNN 24.71
- Support Level
- EDUC $1.19
- IMNN $0.60
- Resistance Level
- EDUC $1.62
- IMNN $1.08
- Average True Range (ATR)
- EDUC 0.15
- IMNN 0.08
- MACD
- EDUC 0.01
- IMNN -0.02
- Stochastic Oscillator
- EDUC 25.58
- IMNN 3.12
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).